The Prescription Drug Affordability Board (PDAB) has revised its affordability review schedule for 2024. In January, the board reviewed insulin products. In May through November, the board will review the prescription drugs listed in the revised table below. One week before the board meeting, click on the drug name to read the affordability review drug report.
Written comments specific to drugs under review and submitted by the deadlines below will be included in the drug reports that are posted one week before the meeting. However, written comments specific to drugs under review may be submitted up until 72 hours before the November board meeting. To submit a comment for affordability review,
complete and submit the public comment form.
Revised board calendar for affordability review of insulin, prescription drugs
Board meeting month and date | Drugs
| Deadline for written materials, specific to drugs under review | Each affordability review will have the following agenda for each drug |
---|
January 26, 2024 - Completed
| Insulin: Tresiba Tresiba FlexTouch Humulin R U-500 KwikPen | - | - |
May 15, 2024 | Ozempic Trulicity | May 5, 2024 | - Staff presentation
- Public comment
* Patients and caregivers * General Public * Manufacturers * Carriers and providers |
June 26, 2024 | Shingrix
Ocrevus | June 16, 2024
| - Staff presentation
- Public Comment
* Patients and caregivers * General Public * Manufacturers * Carriers and providers |
July 24, 2024 | Entyvio
Inflectra | July 14, 2024
| - Staff presentation
- Public Comment
* Patients and caregivers * General Public * Manufacturers * Carriers and providers
|
August 21, 2024 | Cosentyx Skyrizi | August 11, 2024
| - Staff presentation
- Public Comment
* Patients and caregivers * General Public * Manufacturers * Carriers and providers |
September 18, 2024
| Tremfya Vyvanse | September 8, 2024 | - Staff presentation
- Public Comment
* Patients and caregivers * General Public * Manufacturers * Carriers and providers |
October 16, 2024
| Genvoya Triumeq | October 6, 2024
| - Staff presentation
- Public Comment
* Patients and caregivers * General Public * Manufacturers * Carriers and providers
|
November 20, 2024
| |
| - Board business
- Final review of drugs and approval of Legislative recommendations
- General public comments
|